<DOC>
	<DOCNO>NCT00015990</DOCNO>
	<brief_summary>Phase II trial study effectiveness thalidomide treat patient myelodysplastic syndrome . Thalidomide may improve immune system 's ability fight myelodysplastic syndrome</brief_summary>
	<brief_title>Thalidomide Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether thalidomide improves cytopenias patient myelodysplastic syndrome . II . Determine toxicity regimen patient . III . Determine whether regimen regulate peripheral blood level tumor necrosis factor alpha , interferon gamma , interleukin-12 whether change correlate clinical response patient . IV . Determine whether regimen alters peripheral blood T-cell subset distribution whether change correlate clinical response patient . V. Determine effect regimen bone marrow microvessel density whether effect correlate clinical response patient . OUTLINE : This multicenter study . Patients stratify accord prognosis ( favorable v unfavorable ) . ( Favorable stratum close accrual 12/28/01 ) Patients receive oral thalidomide daily . Treatment continue 5 year absence disease progression unacceptable toxicity . Patients follow every 6 month 1 year annually 4 year . PROJECTED ACCRUAL : A total 20-58 patient ( 10-29 per stratum ) accrue study within 20 month . ( Favorable stratum close accrual 12/28/01 )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Pretransfusion hemoglobin = &lt; 10 g/dL Pretransfusion platelet count = &lt; 50,000/μL Absolute neutrophil count &lt; 1000/μL Total bilirubin ≤ 1.5 x UNL Alkaline phosphatase ≤ 3 x UNL AST ≤ 3 x UNL Creatinine ≤ 1.5 x UNL A diagnosis MDS demonstrate bone marrow ; subtypes eligible include : Refractory anemia ( cytopenia ) Refractory anemia ring sideroblast Chronic myelomonocytic leukemia Refractory anemia excess blast Refractory anemia excess blast transformation Unclassified MDS Patients refractory anemia excess blast transformation candidate ( decline ) induction chemotherapy eligible ; patient candidate ( accept ) induction chemotherapy fail least 1 chemotherapy regimen prior entry Patients candidate marrow transplantation option discuss prior study entry Any follow regimen may harmful develop fetus nursing child : Pregnant woman Nursing woman Women childbearing potential sexual partner unwilling employ 2 adequate method contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) Peripheral neuropathy ( history clinical exam ) Concomitant therapy ≤ 30 day myelodysplastic syndrome specific agent include chemotherapy , corticosteroid and/or growth factor ( i.e . erythropoietin , GCSF , GMCSF , thrombopoietic agent ) ; patient chronic lowdose corticosteriods ( &lt; 20 mg/d ) reason MDS allow Uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>